JS007 / Shanghai Junshi Biosci - LARVOL DELTA

JS207, a bispecific antibody targeting PD-1 and VEGF-A, combined with JS007 (anti-CTLA4), for patients with advanced hepatocellular carcinoma in a randomized, multicenter, Phase II study (AACR 2026) - "Abstract is embargoed at this time."

Bispecific • Clinical • Metastases • P2 data • Hepatocellular Cancer • Oncology • Solid Tumor

JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - P2 | N=72 | Recruiting | Sponsor: Shanghai Junshi Bioscience Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Hepatocellular Cancer • Oncology • Solid Tumor

JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - P2 | N=72 | Not yet recruiting | Sponsor: Shanghai Junshi Bioscience Co., Ltd.

New P2 trial • Hepatocellular Cancer • Oncology • Solid Tumor

Preclinical investigations and a first-in-human phase 1a trial of JS007, a novel anti-CTLA-4 antibody, in patients with advanced solid tumors. (PubMed, Exp Hematol Oncol) - P1 | "JS007 preliminarily demonstrates good tolerance and encouraging antitumor activity in patients with previously treated advanced solid tumors."

Journal • Metastases • P1 data • Preclinical • Oncology • Solid Tumor

FD-IMPACT: Newly Emerging Immunotherapy for Pancreatic Cancer Treatment (clinicaltrials.gov) - P1/2 | N=117 | Not yet recruiting | Sponsor: Fudan University

New P1/2 trial • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Cancer • Solid Tumor

A phase Ia first-in-human study of JS007, a novel anti-CTLA-4 monoclonal antibody, in patients with advanced solid tumors (ESMO 2023) - P1 | "Conclusions JS007 is well-tolerated with preliminary promising efficacy in heavily pretreated pts. The dose expansion phase is still ongoing, and the combination of JS007 with the anti-PD-1 antibody toripalimab is planned."

Clinical • Metastases • P1 data • Esophageal Cancer • Gastric Adenocarcinoma • Gastric Cancer • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • CTLA4

Clinical Study of JS007 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1; N=42; Recruiting; Sponsor: Shanghai Junshi Bioscience Co., Ltd.; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Oncology • Solid Tumor

Clinical Study of JS007 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1; N=42; Not yet recruiting; Sponsor: Shanghai Junshi Bioscience Co., Ltd.

Clinical • New P1 trial • Oncology • Solid Tumor

Junshi Bio’s CTLA-4 mAb JS007 gets first trial nod in China (GBI Health) - "Shanghai-based biotech Junshi Biosciences (HKEX:1877; SSE:688180) announced clinical trial approval from the National Medical Products Administration (NMPA) for its JS007. The targeted indication is advanced malignant tumors."

Non-US regulatory • Oncology

Junshi Bio’s CTLA-4 mAb JS007 under trial review in China (GBI Health) - "Shanghai-based biotech Junshi Biosciences (HKEX:1877; SSE:688180) announced that the clinical approval filing for its JS007 has been accepted for review by the National Medical Products Administration. JS007, an in-house developed humanized CTLA-4 monoclonal antibody, is under development to treat advanced malignant tumors."

Non-US regulatory • Oncology